Solara Active Pharma Sciences (NSE:SOLARAPP1) Long-Term Debt: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SOLARAPP1 Solara Active Pharma Sciences Ltd NSE:SOLARAPP1
71 GF Score
Price ₹267.45
GF Value ₹287.91
! 3 Warning Signs
View Full Analysis

What is Solara Active Pharma Sciences Long-Term Debt?

Solara Active Pharma Sciences NSE:SOLARAPP1 71 Long-Term Debt is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:SOLARAPP1 with a GF Score™ of 71/100 and a GF Value™ of ₹287.91. The stock has 3 warning signs investors should review.

Solara Active Pharma Sciences's Long-Term Debt for the quarter that ended in Jun. 2026 was ₹0 Mil.

Solara Active Pharma Sciences's quarterly Long-Term Debt increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹1,105 Mil) but then declined from Mar. 2026 (₹1,105 Mil) to Jun. 2026 (₹0 Mil).

Solara Active Pharma Sciences's annual Long-Term Debt increased from Mar. 2024 (₹1,058 Mil) to Mar. 2025 (₹1,139 Mil) but then declined from Mar. 2025 (₹1,139 Mil) to Mar. 2026 (₹1,105 Mil).

Solara Active Pharma Sciences  (NSE:SOLARAPP1) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Solara Active Pharma Sciences Long-Term Debt Related Terms

Solara Active Pharma Sciences Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Solara Active Pharma Sciences's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solara Active Pharma Sciences Long-Term Debt Chart

Solara Active Pharma Sciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,830.40 2,351.00 1,058.30 1,138.60 1,104.50

Solara Active Pharma Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 848.80 0.00 1,104.50 0.00
NSE:SOLARAPP1
71GF Score
Solara Active Pharma Sciences Ltd NSE:SOLARAPP1
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ₹0 Mil mean?
Solara Active Pharma Sciences (NSE:SOLARAPP1) has a Long-Term Debt of ₹0 Mil as of Jun. 2026.
Is Solara Active Pharma Sciences' Long-Term Debt too high?
Solara Active Pharma Sciences' current Long-Term Debt is ₹0 Mil. Overall, Solara Active Pharma Sciences has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Solara Active Pharma Sciences' Long-Term Debt compare to ZTS?
Solara Active Pharma Sciences' Long-Term Debt of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Solara Active Pharma Sciences's current Long-Term Debt is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solara Active Pharma Sciences stock overvalued right now?
Solara Active Pharma Sciences (NSE:SOLARAPP1) has a current Long-Term Debt of ₹0 Mil. The stock's GF Value™ is ₹287.91, compared to a current price of ₹267.45 — trading 7.1% below its estimated fair value. The current Long-Term Debt is ₹0 Mil. Solara Active Pharma Sciences' overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Solara Active Pharma Sciences (NSE:SOLARAPP1), the current Long-Term Debt is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Solara Active Pharma Sciences (NSE:SOLARAPP1) Overvalued in 2026?

Based on GuruFocus' analysis, Solara Active Pharma Sciences stock appears to be undervalued. The current stock price of ₹267.45 is trading 7.1% below its estimated GF Value™ of ₹287.91.

Key valuation signals for NSE:SOLARAPP1:

  • Long-Term Debt: ₹0 Mil
  • GF Value™: ₹287.91 vs. price of ₹267.45 (7.1% below fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the NSE:SOLARAPP1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Solara Active Pharma Sciences Business Description

Other Exchanges SOLARA:India541540:India
Address Phase II - CSIR Road, Module No. 601, 602, 603, Ticel Bio Park, Taramani, Chennai, TN, IND, 600113
Solara Active Pharma Sciences Ltd is engaged in the Active Pharmaceutical Ingredients (API) in India. It manufactures and develops APIs and offers services, including CRAMS and contract manufacturing for APIs. The company offers products and services, such as Anaesthetic, Analgesics, Antiviral, Retinoid, Anti-emetic, Antimalarial, Diuretic, Muscle relaxant, Antiallergics, Antihypertensive, Calcimimetic agent, Anti-seizure, Antigout, Cardiovascular, Anti-infective, Cough suppressant, and others. It also offers contract services, including contract development and manufacturing, and analytical services. Geographically, the company generates all of its revenue from India.
71GF Score

Get the complete analysis for NSE:SOLARAPP1

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹267.45
Price
₹287.91
GF Value